Enhanced cytotoxic activity of Moringa oleifera-loaded pharmacosomes against neuroblastoma.

This laboratory study investigated whether packaging Moringa oleifera extract into specialized nanocarriers called pharmacosomes could improve its cancer-fighting properties against neuroblastoma, a serious childhood brain cancer. Neuroblastoma has poor outcomes in high-risk cases, creating urgent need for better treatments. The researchers faced a common problem with plant extracts: moringa's beneficial compounds don't dissolve well in water and break down easily, limiting their medical usefulness. To solve this, they created tiny spherical packages made from lecithin and chitosan (natural compounds) to carry the moringa extract. These nanocarriers, measuring 41-190 nanometers across, successfully trapped over 94% of the moringa extract and remained stable. When tested on neuroblastoma cancer cells in laboratory dishes, the packaged moringa extract was dramatically more effective than regular moringa extract, requiring 10 times less material to kill the same number of cancer cells. The treatment worked by disrupting the cancer cells' ability to divide and multiply normally, causing them to get stuck in specific phases of cell division. Importantly, the empty nanocarriers showed minimal toxicity to normal human cells, suggesting the treatment could be selective for cancer cells. This research demonstrates that nanotechnology packaging can significantly enhance moringa's anticancer potential, though the work remains in early laboratory stages.